How do I set a price alert for GFC-M.TA?

To set a GFC-M.TA price alert on Stock Alarm Pro, navigate to the GFC-M.TA quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for GFC-M.TA?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for GFC-M.TA. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for GFC-M.TA?

Stock Alarm Pro supports over 125 trigger types for GFC-M.TA: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about GFC-M.TA price changes?

GFC-M.TA alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for GFC-M.TA alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for GFC-M.TA and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

GFC-M.TA Company Intelligence - Business Model, Drivers & Risks

GFC-M.TA(GFC-M.TA)

$1603.00—Stale · unknown old

WatchlistAsk SA Chart

GFC-M.TA(GFC-M.TA)

TLV • Last print unknown ago

$1603.00—Stale · unknown old

WatchlistAsk SA Chart Studio

GFC-M.TA(GFC-M.TA)

GFC-M.TA

G.F.C Green Fields Capital Ltd. is a biotechnology company focused on developing innovative healthcare solutions, particularly in the field of regenerative medicine. Its unique competitive advantage lies in its proprietary technology platform that enables the rapid development of biologics, which is crucial for addressing unmet medical needs in various therapeutic areas.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and regulatory compliance, which limits its ability to scale quickly without significant revenue growth.

Business Overview

01Research and development collaborations (estimated 70%)

02Licensing agreements (estimated 20%)

03Product sales (estimated 10%)

G.F.C Green Fields Capital generates revenue primarily through partnerships with larger pharmaceutical companies for R&D projects, leveraging its proprietary technology to enhance drug development efficiency. The company also earns income from licensing its technology and potential future product sales once its pipeline matures.

What Moves the Stock

Progress in clinical trials for key pipeline products, particularly in regenerative therapies

Partnership announcements with major pharmaceutical companies

Regulatory approvals for new therapies

Market sentiment towards the biotechnology sector

Watch on Earnings

Clinical trial milestones achievedPartnership revenue updatesRegulatory approval timelines

Risk Factors

Regulatory changes that could impact drug approval processes

Technological disruption from competitors developing superior therapies

Emergence of new entrants in the regenerative medicine space

Rapid advancements in biotechnology that could outpace GFC's current offerings

High debt levels (Debt/Equity of 1.90) could limit financial flexibility

Low liquidity due to minimal revenue generation

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D can fluctuate with overall economic conditions and investor sentiment.

Interest Rates

Higher interest rates can increase the cost of capital for biotech firms, impacting their ability to finance R&D projects and potentially dampening investor appetite for high-risk stocks.

Credit

minimal - The company is not heavily reliant on credit markets for financing due to its current low revenue generation.

Live Conditions

Russell 2000 FuturesS&P 500 FuturesDow Jones Futures